Literature DB >> 1700653

Human basophil releasability. VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma.

V Casolaro1, G Spadaro, G Marone.   

Abstract

We evaluated basophil releasability in two groups of allergic patients with positive skin tests to Dermatophagoides pteronyssinus major allergen (Der p l) (29 adults with bronchial asthma and 17 with allergic rhinitis) and in 31 age-matched normal donors. Both basophil reactivity (maximal percent histamine release) and basophil sensitivity (the concentration that causes 50% of maximal percent histamine release: HC50) to Der p l in patients with asthma were similar to those in patients with allergic rhinitis. On the contrary, basophil reactivity to anti-IgE was significantly higher in patients with asthma (58.0 +/- 3.6%) than in patients with allergic rhinitis (46.3 +/- 5.2%; p less than 0.05). Both groups of patients showed an increased releasability compared to control subjects (27.3 +/- 4.6%; p less than 0.001), whereas there were no significant differences in basophil sensitivity to anti-IgE among the three groups of donors. Differences were also found with respect to basophil reactivity and sensitivity to f-met peptide, whereas no differences appeared when basophils from the three groups of donors were challenged with the Ca2+ ionophore A23187. There was a significant correlation between basophil reactivity and sensitivity to Der p l and to anti-IgE in both asthmatic and allergic rhinitis patients. A significant correlation was found between basophil reactivity and sensitivity to anti-IgE and serum IgE level only in patients with bronchial asthma, whereas no correlations were found in patients with allergic rhinitis. There was no correlation between in vivo mast cell releasability and in vitro basophil releasability in response to Der p l in either group of allergic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700653     DOI: 10.1164/ajrccm/142.5.1108

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

1.  Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.

Authors:  Donald W Macglashan; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2013-06-20       Impact factor: 10.793

2.  IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells.

Authors:  Remo Poto; Isabella Quinti; Gianni Marone; Maurizio Taglialatela; Amato de Paulis; Vincenzo Casolaro; Gilda Varricchi
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

3.  Comparative analysis of biological activities of Der p I-derived peptides on Fc epsilon receptor-bearing cells from Dermatophagoides pteronyssinus-sensitive patients.

Authors:  P Jeannin; J Pestel; M Bossus; P Lassalle; A Tartar; A B Tonnel
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

4.  Histamine release from basophils in childhood: age dependency and inhibition by pertussis infection and pertussis toxin.

Authors:  M Griese; G Merkel; R Feldmann; I Bergfeld; D Reinhardt
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

5.  Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils.

Authors:  G Marone; C Stellato; A Renda; A Genovese
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Histamine inhibits the production of interleukin-12 through interaction with H2 receptors.

Authors:  T C van der Pouw Kraan; A Snijders; L C Boeije; E R de Groot; A E Alewijnse; R Leurs; L A Aarden
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

7.  Interleukin-4 (IL-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo.

Authors:  B Niggemann; T Zuberbier; U Herz; K Enssle; U Wahn; H Renz
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.